Related references
Note: Only part of the references are listed.The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia
Martina Rudelius et al.
VIRCHOWS ARCHIV (2023)
Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
Alexander Waclawiczek et al.
CANCER DISCOVERY (2023)
Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis
Riccardo Masetti et al.
BLOOD ADVANCES (2023)
Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients
Julia Stomper et al.
CLINICAL EPIGENETICS (2021)
Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naive higher-risk myelodysplastic syndromes.
Amer Methqal Zeidan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
EZH2/EHMT2 Histone Methyltransferases Inhibit the Transcription of DLX5 and Promote the Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia
Zhuanzhen Zheng et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes
Sushree S. Sahoo et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia
Amanda C. Winters et al.
PEDIATRIC BLOOD & CANCER (2020)
Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?
Emery H. Bresnick et al.
BLOOD ADVANCES (2020)
Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes
Kathy L. McGraw et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
BH3-only proteins target BCL-xL/MCL-1, not BAX/BAK, to initiate apoptosis
Kai Huang et al.
CELL RESEARCH (2019)
Aberrant Expression of EZH2 in Pediatric Patients with Myelodysplastic Syndrome: A Potential Biomarker of Leukemic Evolution
Teresa de Souza Fernandez et al.
Biomed Research International (2019)
The BCL-2 arbiters of apoptosis and their growing role as cancer targets
Jerry M. Adams et al.
CELL DEATH AND DIFFERENTIATION (2018)
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia
Stefanie Goellner et al.
NATURE MEDICINE (2017)
Heterogeneity of GATA2-related myeloid neoplasms
Shinsuke Hirabayashi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
Elias Jabbour et al.
BLOOD (2017)
Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents
Marcin W. Wlodarski et al.
BLOOD (2016)
Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients
S. Jilg et al.
LEUKEMIA (2016)
Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome
Michaela Novakova et al.
HAEMATOLOGICA (2016)
Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome
Michaela Novakova et al.
HAEMATOLOGICA (2016)
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity
Michael A. Spinner et al.
BLOOD (2014)
The KDM2B-Let-7b-EZH2 Axis in Myelodysplastic Syndromes as a Target for Combined Epigenetic Therapy
Ekapun Karoopongse et al.
PLOS ONE (2014)
High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia
Marlene Pasquet et al.
BLOOD (2013)
The myelodysplastic syndrome as a prototypical epigenetic disease
Jean-Pierre J. Issa
BLOOD (2013)
Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring
Feng Xu et al.
ANNALS OF HEMATOLOGY (2011)
Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency
Rachel Emma Dickinson et al.
BLOOD (2011)
Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome
Amy P. Hsu et al.
BLOOD (2011)
Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications
Katherine R. Calvo et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome)
Pia Ostergaard et al.
NATURE GENETICS (2011)
Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia
Christopher N. Hahn et al.
NATURE GENETICS (2011)
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
Maria E. Figueroa et al.
BLOOD (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
The Polycomb group protein EZH2 directly controls DNA methylation
E Viré et al.
NATURE (2006)
Role of histone H3 lysine 27 methylation in polycomb-group silencing
R Cao et al.
SCIENCE (2002)
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics
A Letai et al.
CANCER CELL (2002)
Expression and prognostic significance of Bcl-2 family proteins in Myelodysplastic syndromes
D Boudard et al.
AMERICAN JOURNAL OF HEMATOLOGY (2002)
Share Paper
